Skip to Content
Merck
All Photos(1)

Documents

N-038

Supelco

6β-Naltrexol solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C20H25NO4
CAS Number:
Molecular Weight:
343.42
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

forensics and toxicology

format

single component solution

storage temp.

2-8°C

SMILES string

OC1=C(O2)C([C@]([C@@H]2[C@H](O)CC3)(CCN4CC5CC5)[C@]3(O)[C@H]4C6)=C6C=C1

InChI

1S/C20H25NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,14-15,18,22-24H,1-2,5-10H2/t14-,15-,18+,19+,20-/m1/s1

InChI key

JLVNEHKORQFVQJ-PYIJOLGTSA-N

General description

6ß-Naltrexol is the primary urinary metabolite of Naltrexone, an opiate sold under the trade names Revia, Depade, and Vivitrol® and used primarily in the management of alcohol or opiate dependence. This analytical reference standard is appropriate for use in LC/MS or GC/MS applications from clinical toxicology and forensic analysis to urine drug testing.

Application



  • Advanced analytical techniques for pharmacokinetics: The development of a rapid and sensitive gas chromatography-mass spectrometry method for nalmefene quantification in human plasma, pivotal for pharmacokinetic studies, underscores the importance of 6β-Naltrexol in therapeutic drug monitoring and addiction treatment research (Xie et al., 2002).



Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Vivitrol is a registered trademark of Alkermes, Inc.

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Target Organs

Eyes

Storage Class Code

3 - Flammable liquids

WGK

WGK 1

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Waleed O Farid et al.
PloS one, 7(12), e52812-e52812 (2013-01-10)
Naltrexone is not recommended during pregnancy. However, sustained-release naltrexone implant use in humans has resulted in cases of inadvertent foetal exposure. Here, we used clinically relevant dosing to examine the effects of maternally administered sustained-release naltrexone on the rat brain
Stan L Banks et al.
Pharmaceutical research, 25(7), 1677-1685 (2008-05-02)
The purpose of this investigation was to evaluate the in vitro microneedle (MN) enhanced percutaneous absorption of naltrexone hydrochloride salt (NTX x HCl) compared to naltrexone base (NTX) in hairless guinea pig skin (GP) and human abdominal skin. In a
Ling-Di Yan et al.
Yao xue xue bao = Acta pharmaceutica Sinica, 44(7), 722-725 (2009-10-08)
The pharmacokinetics of 6beta-naltrexol (6beta-NOL) following single intramuscular administration and multiple intramuscular injection once per day for seven days was studied in 4 Beagle dogs. Plasma concentration of 6beta-NOL in dogs was analyzed by a combination of high performance liquid
Mary F Divin et al.
European journal of pharmacology, 583(1), 48-55 (2008-02-16)
It has been proposed that on chronic morphine treatment the micro-opioid receptor becomes constitutively active, and as a consequence, the opioid withdrawal response arises from a reduction in the level of this constitutively active receptor. In support of this, the
Franklin K Johnson et al.
Clinical therapeutics, 32(6), 1149-1164 (2010-07-20)
Morphine sulfate/sequestered naltrexone hydrochloride (HCl) (MS-sNT) extended-release fixed-dose combination capsules, approved by the US Food and Drug Administration (FDA) in August 2009 for chronic moderate to severe pain, contain extended-release morphine pellets with a sequestered core of the opioid antagonist

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service